biocon biologics uk limited
biocon biologics uk limited Company Information
Company Number
10038295
Next Accounts
Dec 2025
Industry
Activities of other holding companies (not including agricultural, production, construction, distribution and financial services holding companies) n.e.c.
Research and experimental development on biotechnology
Shareholders
biocon biologics limited
Group Structure
View All
Contact
Registered Address
16 great queen street, covent garden, london, WC2B 5AH
Website
www.biocon.combiocon biologics uk limited Estimated Valuation
Pomanda estimates the enterprise value of BIOCON BIOLOGICS UK LIMITED at £475m based on a Turnover of £164m and 2.9x industry multiple (adjusted for size and gross margin).
biocon biologics uk limited Estimated Valuation
Pomanda estimates the enterprise value of BIOCON BIOLOGICS UK LIMITED at £489.9m based on an EBITDA of £45.6m and a 10.74x industry multiple (adjusted for size and gross margin).
biocon biologics uk limited Estimated Valuation
Pomanda estimates the enterprise value of BIOCON BIOLOGICS UK LIMITED at £1.6b based on Net Assets of £1b and 1.58x industry multiple (adjusted for liquidity).
Edit your figures and get a professional valuation report.
Biocon Biologics Uk Limited Overview
Biocon Biologics Uk Limited is a live company located in london, WC2B 5AH with a Companies House number of 10038295. It operates in the activities of other holding companies n.e.c. sector, SIC Code 64209. Founded in March 2016, it's largest shareholder is biocon biologics limited with a 100% stake. Biocon Biologics Uk Limited is a young, mega sized company, Pomanda has estimated its turnover at £164m with healthy growth in recent years.
Upgrade for unlimited company reports & a free credit check
Biocon Biologics Uk Limited Health Check
Pomanda's financial health check has awarded Biocon Biologics Uk Limited a 4 rating. We use a traffic light system to show it exceeds the industry average on 4 measures and has 6 areas for improvement. Company Health Check FAQs
4 Strong
1 Regular
6 Weak
Size
annual sales of £164m, make it larger than the average company (£11.6m)
£164m - Biocon Biologics Uk Limited
£11.6m - Industry AVG
Growth
3 year (CAGR) sales growth of 6%, show it is growing at a slower rate (12.5%)
6% - Biocon Biologics Uk Limited
12.5% - Industry AVG
Production
with a gross margin of 44.6%, this company has a comparable cost of product (44.6%)
44.6% - Biocon Biologics Uk Limited
44.6% - Industry AVG
Profitability
an operating margin of 27.8% make it more profitable than the average company (-2.8%)
27.8% - Biocon Biologics Uk Limited
-2.8% - Industry AVG
Employees
with 1 employees, this is below the industry average (76)
1 - Biocon Biologics Uk Limited
76 - Industry AVG
Pay Structure
on an average salary of £172.7k, the company has a higher pay structure (£63.2k)
£172.7k - Biocon Biologics Uk Limited
£63.2k - Industry AVG
Efficiency
resulting in sales per employee of £164m, this is more efficient (£160.1k)
£164m - Biocon Biologics Uk Limited
£160.1k - Industry AVG
Debtor Days
it gets paid by customers after 142 days, this is later than average (49 days)
142 days - Biocon Biologics Uk Limited
49 days - Industry AVG
Creditor Days
its suppliers are paid after 41 days, this is quicker than average (50 days)
41 days - Biocon Biologics Uk Limited
50 days - Industry AVG
Stock Days
There is insufficient data available for this Key Performance Indicator!
- - Biocon Biologics Uk Limited
- - Industry AVG
Cash Balance
has cash to cover current liabilities for 8 weeks, this is less cash available to meet short term requirements (24 weeks)
8 weeks - Biocon Biologics Uk Limited
24 weeks - Industry AVG
Debt Level
it has a ratio of liabilities to total assets of 15.3%, this is a lower level of debt than the average (58.9%)
15.3% - Biocon Biologics Uk Limited
58.9% - Industry AVG
BIOCON BIOLOGICS UK LIMITED financials
Biocon Biologics Uk Limited's latest turnover from March 2024 is £164 million and the company has net assets of £1 billion. According to their latest financial statements, Biocon Biologics Uk Limited has 1 employee and maintains cash reserves of £16.7 million as reported in the balance sheet.
Data source: Companies House, Pomanda Estimates
| Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 | |
|---|---|---|---|---|---|---|---|---|
| Turnover | 164,010,896 | 184,960,866 | 172,741,415 | 137,457,863 | 128,340,173 | 86,210,629 | 42,523,838 | 34,134,644 |
| Other Income Or Grants | ||||||||
| Cost Of Sales | ||||||||
| Gross Profit | ||||||||
| Admin Expenses | ||||||||
| Operating Profit | 45,624,616 | 45,981,430 | 35,881,025 | 28,810,640 | 26,247,252 | 41,680,824 | -4,174,472 | -981,469 |
| Interest Payable | 2,518,416 | 1,756,446 | 292,600 | 57,892 | 15,389 | 10,524 | 5,980,753 | 99,048 |
| Interest Receivable | 1,153,314 | 517,955 | 7,254 | 13,190 | 57,892 | 24,806 | 38,204 | 20,596 |
| Pre-Tax Profit | 44,259,515 | 44,742,940 | 35,595,680 | 28,765,939 | 26,289,755 | 41,677,817 | -10,117,021 | -1,059,920 |
| Tax | -14,113,720 | -5,936,924 | -8,416,895 | -4,445,259 | -5,962,920 | -6,657,897 | 204,062 | -204,061 |
| Profit After Tax | 30,145,795 | 38,806,016 | 27,178,784 | 24,320,680 | 20,326,836 | 35,019,920 | -9,912,959 | -1,263,981 |
| Dividends Paid | 0 | 0 | 0 | 0 | 4,763,301 | 0 | 0 | 0 |
| Retained Profit | 30,145,795 | 38,806,016 | 27,178,784 | 24,320,680 | 15,563,535 | 35,019,920 | -9,912,959 | -1,263,981 |
| Employee Costs | 172,652 | 389,042 | 276,479 | 4,840,246 | 1,297,816 | 0 | 9,829,152 | 3,085,381 |
| Number Of Employees | 1 | 1 | 1 | 14 | 6 | 547 | 477 | |
| EBITDA* | 45,624,616 | 45,981,430 | 46,024,503 | 28,810,640 | 30,946,797 | 42,445,313 | -3,411,222 | -218,218 |
* Earnings Before Interest, Tax, Depreciation and Amortisation
| Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 | |
|---|---|---|---|---|---|---|---|---|
| Tangible Assets | 0 | 0 | 380,926,165 | 269,077,385 | 164,968,489 | 87,876,419 | 216,865,169 | 214,976,124 |
| Intangible Assets | 70,135,820 | 69,389,196 | 85,783,492 | 83,298,402 | 84,381,504 | 76,711,268 | 87,311,312 | 60,286,287 |
| Investments & Other | 1,055,986,034 | 978,598,834 | 380,926,164 | 269,077,385 | 163,052,909 | 87,876,418 | 42,468 | 42,468 |
| Debtors (Due After 1 year) | 0 | 0 | 0 | 0 | 957,789 | 0 | 0 | 0 |
| Total Fixed Assets | 1,126,121,854 | 1,047,988,029 | 466,709,656 | 352,375,787 | 248,392,202 | 164,587,686 | 304,176,481 | 275,262,410 |
| Stock & work in progress | 0 | 0 | 0 | 0 | 0 | 0 | 7,496,929 | 7,758,239 |
| Trade Debtors | 63,873,542 | 32,371,854 | 25,586,813 | 11,160,047 | 12,085,593 | 16,798,467 | 0 | 0 |
| Group Debtors | 20,578,575 | 24,068,446 | 1,454,941 | 17,855,049 | 5,079,876 | 0 | 0 | 0 |
| Misc Debtors | 1,671,270 | 4,552,639 | 21,352,571 | 18,230,983 | 15,060,090 | 1,635,721 | 25,031,410 | 12,394,977 |
| Cash | 16,665,899 | 38,774,555 | 6,186,522 | 5,323,171 | 11,131,467 | 19,597,083 | 11,865,678 | 7,939,277 |
| misc current assets | 1,001,381 | 270,872 | 19,123,811 | 0 | 0 | 13,719,462 | 4,123,874 | 3,172,274 |
| total current assets | 103,790,669 | 100,038,367 | 73,704,659 | 52,569,251 | 43,357,028 | 51,750,733 | 48,517,893 | 31,264,768 |
| total assets | 1,229,912,523 | 1,148,026,397 | 540,414,315 | 404,945,038 | 291,749,230 | 216,338,419 | 352,694,374 | 306,527,178 |
| Bank overdraft | 0 | 0 | 0 | 47,633,006 | 0 | 0 | 0 | 0 |
| Bank loan | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Trade Creditors | 10,250,921 | 14,610,190 | 18,890,053 | 16,232,596 | 11,403,342 | 15,350,673 | 0 | 0 |
| Group/Directors Accounts | 56,108,809 | 36,314,457 | 1 | 0 | 0 | 1 | 1 | 0 |
| other short term finances | 25,525,629 | 10,091,313 | 1,056,746 | 0 | 0 | 0 | 23,931,000 | 8,894,523 |
| hp & lease commitments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| other current liabilities | 7,589,779 | 10,575,506 | 70,422,374 | 39,982,411 | 80,699,104 | 33,518,002 | 51,978,127 | 51,579,900 |
| total current liabilities | 99,475,138 | 71,591,467 | 90,369,176 | 103,848,014 | 92,102,448 | 48,868,676 | 75,909,129 | 60,474,425 |
| loans | 40,477,286 | 65,799,570 | 159,197,162 | 49,006,302 | 0 | 0 | 340,558,331 | 380,773,557 |
| hp & lease commitments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accruals and Deferred Income | 38,885,052 | 57,209,944 | 54,259,229 | 49,381,503 | 39,227,612 | 17,841,840 | 2,247,046 | 2,469,138 |
| other liabilities | 643,799 | 1,978,974 | 2,066,741 | 3,274,219 | 5,916,019 | 7,105,915 | 0 | 0 |
| provisions | 8,688,612 | 8,910,374 | 19,276,156 | 0 | 0 | 0 | 0 | 0 |
| total long term liabilities | 88,694,751 | 133,898,864 | 145,562,630 | 77,158,874 | 45,143,631 | 24,947,756 | 172,873,558 | 193,208,718 |
| total liabilities | 188,169,890 | 205,490,331 | 235,931,806 | 181,006,888 | 137,246,079 | 73,816,432 | 248,782,687 | 253,683,143 |
| net assets | 1,041,742,634 | 942,536,065 | 304,482,509 | 223,938,150 | 154,503,151 | 142,521,987 | 103,911,687 | 52,844,035 |
| total shareholders funds | 1,041,742,634 | 942,536,065 | 304,482,508 | 223,938,150 | 154,503,151 | 142,521,988 | 103,911,686 | 52,844,036 |
| Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 | |
|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||
| Operating Profit | 45,624,616 | 45,981,430 | 35,881,025 | 28,810,640 | 26,247,252 | 41,680,824 | -4,174,472 | -981,469 |
| Depreciation | 0 | 0 | 0 | 0 | 0 | 0 | 763,251 | 763,251 |
| Amortisation | 0 | 0 | 10,143,478 | 0 | 4,699,545 | 764,489 | 0 | 0 |
| Tax | -14,113,720 | -5,936,924 | -8,416,895 | -4,445,259 | -5,962,920 | -6,657,897 | 204,062 | -204,061 |
| Stock | 0 | 0 | 0 | 0 | 0 | -7,496,929 | -261,310 | 7,758,239 |
| Debtors | 25,130,448 | 12,598,615 | 1,148,246 | 14,062,730 | 14,749,162 | -6,597,223 | 12,636,433 | 12,394,977 |
| Creditors | -4,359,269 | -4,279,863 | 2,657,458 | 4,829,254 | -3,947,331 | 15,350,673 | 0 | 0 |
| Accruals and Deferred Income | -21,310,619 | -56,896,153 | 35,317,689 | -30,562,802 | 68,566,874 | -2,865,331 | 176,135 | 54,049,038 |
| Deferred Taxes & Provisions | -221,762 | -10,365,782 | 19,276,156 | 0 | 0 | 0 | 0 | 0 |
| Cash flow from operations | -19,511,202 | -44,095,907 | 93,710,665 | -15,430,897 | 74,854,258 | 62,366,910 | -15,406,147 | 33,473,543 |
| Investing Activities | ||||||||
| capital expenditure | ||||||||
| Change in Investments | 77,387,201 | 597,672,670 | 111,848,779 | 106,024,476 | 75,176,491 | 87,833,950 | 0 | 42,468 |
| cash flow from investments | ||||||||
| Financing Activities | ||||||||
| Bank loans | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Group/Directors Accounts | 19,794,352 | 36,314,456 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Short Term Loans | 15,434,316 | 9,034,567 | 1,056,746 | 0 | 0 | -23,931,000 | 15,036,477 | 8,894,523 |
| Long term loans | -25,322,284 | -93,397,592 | 110,190,860 | 49,006,302 | 0 | -340,558,331 | -40,215,226 | 380,773,557 |
| Hire Purchase and Lease Commitments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| other long term liabilities | -1,335,175 | -87,767 | -1,207,478 | -2,641,800 | -1,189,896 | 7,105,915 | 0 | 0 |
| share issue | ||||||||
| interest | -1,365,102 | -1,238,491 | -285,346 | -44,702 | 42,503 | 14,282 | -5,942,549 | -78,452 |
| cash flow from financing | 76,266,880 | 549,872,714 | 163,120,356 | 91,434,119 | -4,729,764 | -353,778,753 | 29,859,311 | 443,697,645 |
| cash and cash equivalents | ||||||||
| cash | -22,108,656 | 32,588,033 | 863,351 | -5,808,296 | -8,465,616 | 7,731,405 | 3,926,401 | 7,939,277 |
| overdraft | 0 | 0 | -47,633,006 | 47,633,006 | 0 | 0 | 0 | 0 |
| change in cash | -22,108,656 | 32,588,033 | 48,496,357 | -53,441,302 | -8,465,616 | 7,731,405 | 3,926,401 | 7,939,277 |
biocon biologics uk limited Credit Report and Business Information
Biocon Biologics Uk Limited Competitor Analysis
Perform a competitor analysis for biocon biologics uk limited by selecting its closest rivals, whether from the FINANCIAL AND INSURANCE ACTIVITIES sector, other mega companies, companies in WC2B area or any other competitors across 12 key performance metrics.
biocon biologics uk limited Ownership
BIOCON BIOLOGICS UK LIMITED group structure
Biocon Biologics Uk Limited has 1 subsidiary company.
Ultimate parent company
BIOCON BIOLOGICS LTD
#0131636
1 parent
BIOCON BIOLOGICS UK LIMITED
10038295
1 subsidiary
biocon biologics uk limited directors
Biocon Biologics Uk Limited currently has 6 directors. The longest serving directors include Mr John Walls (Mar 2016) and Mr Daniel Bradbury (Jul 2019).
| officer | country | age | start | end | role |
|---|---|---|---|---|---|
| Mr John Walls | 80 years | Mar 2016 | - | Director | |
| Mr Daniel Bradbury | United Kingdom | 63 years | Jul 2019 | - | Director |
| Ravi Mazumdar | United Kingdom | 69 years | Jan 2021 | - | Director |
| Mr Paul Blackburn | United Kingdom | 70 years | Jan 2021 | - | Director |
| Mr Nicholas Haggar | United Kingdom | 59 years | Nov 2023 | - | Director |
| Mr Rajendra Jatar | United Kingdom | 58 years | Jan 2024 | - | Director |
P&L
March 2024turnover
164m
-11%
operating profit
45.6m
-1%
gross margin
44.7%
+0.23%
turnover
Turnover, or revenue, is the amount of sales generated by a company within the financial year.
Balance Sheet
March 2024net assets
1b
+0.11%
total assets
1.2b
+0.07%
cash
16.7m
-0.57%
net assets
Total assets minus all liabilities
Similar Companies
biocon biologics uk limited company details
company number
10038295
Type
Private limited with Share Capital
industry
64209 - Activities of other holding companies (not including agricultural, production, construction, distribution and financial services holding companies) n.e.c.
72110 - Research and experimental development on biotechnology
incorporation date
March 2016
age
9
incorporated
UK
ultimate parent company
accounts
Full Accounts
last accounts submitted
March 2024
previous names
biocon biologics limited (October 2020)
accountant
-
auditor
KPMG LLP
address
16 great queen street, covent garden, london, WC2B 5AH
Bank
HDFC BANK LIMITED-HONG KONG
Legal Advisor
-
biocon biologics uk limited Charges & Mortgages
A charge, or mortgage, refers to the rights a company gives to a lender in return for a loan, often in the form of security given over business assets.
We found 6 charges/mortgages relating to biocon biologics uk limited. Currently there are 4 open charges and 2 have been satisfied in the past.
biocon biologics uk limited Capital Raised & Share Issues BETA
When a company issues new shares, e.g. to new investors following a funding round, it is required to notify Companies House within one month of making an allotment of shares.
Click to start generating capital raising & share issue transactions for BIOCON BIOLOGICS UK LIMITED. This can take several minutes, an email will notify you when this has completed.
biocon biologics uk limited Companies House Filings - See Documents
| date | description | view/download |
|---|
